Research today. Impact tomorrow.

25% Off the entire catalogue →

Same standards. Greater possibilities.

Research Use Only18+Not for Human ConsumptionReconstitution Materials Not Supplied
Peptide Database

Cognitive & neurological research

P21 (P021): Research Overview

Peptide derived from a nerve growth factor, studied in Alzheimer's disease models in mice.

Also known as P021 · CNTF-derived peptide

Research use onlyStrongest evidence: animal studyReviewed
DatabaseReferences

What is P21?

P21 is a nootropic peptide derived from ciliary neurotrophic factor (CNTF) that enhances neurogenesis and cognitive function. It contains an adamantane moiety that enables blood-brain barrier penetration. Research shows it increases BDNF expression, inhibits LIF signaling to promote neurogenesis, and reduces tau and amyloid pathology in Alzheimer's disease models.

What is P21 researched for?

  • P021 markedly reduced tau pathology, attenuated Aβ generation, and rescued episodic memory impairment in 3xTg-AD mice.
  • Treatment during synaptic compensation period can prevent neurodegeneration and reduce mortality.
  • Robust attenuation of tau pathologies through BDNF/TrkB/PI3-K/AKT/GSK3β pathway.
  • Enhances dentate gyrus neurogenesis so effectively it exceeds levels in healthy untreated brains.
  • Enhances memory processes through increased BDNF and restored synaptic function.
  • May reduce natural decline in learning and memory in aged models by rescuing neurogenesis deficit.
  • Restores synaptic deficits in cortex and hippocampus.
  • Rescues deficits in neuronal plasticity.

How does P21 work?

P21 operates through multiple pathways: it inhibits leukemia inhibitory factor (LIF) signaling, removing a key roadblock to neurogenesis and shifting the brain toward a more embryologic state favoring neuron growth. It increases brain-derived neurotrophic factor (BDNF) expression and activates the BDNF/TrkB/PI3-K/AKT/GSK3β pathway.

Reported targets: TrkB

References

  1. P021 Treatment in 3xTg-AD Mice Journal of Alzheimer's Disease

    2018

    P021 markedly reduced tau pathology, attenuated Aβ, rescued episodic memory, and reduced mortality in AD mice.

    Animal study

  2. P21 and BDNF/TrkB Pathway Neuropharmacology

    2019

    Disease-modifying effect via BDNF/TrkB/PI3-K/AKT/GSK3β pathway; rescued neurogenesis and cognition.

  3. P21 in Cognitive Aging Neurobiology of Aging

    2017

    May reduce age-related cognitive decline by restoring BDNF expression and synaptic function.

  4. P21 as Promising AD Drug Candidate Alzheimer's

    Research & Therapy · 2020

    Beneficial effects in preclinical studies make P21 highly promising for AD drug development.

Common questions

Can P21 boost neurogenesis above healthy brain levels?

Remarkably, yes. The file states P21 can boost neurogenesis in diseased brains above levels seen in healthy untreated brains. This is extraordinary—most treatments aim to restore function, but P21 may actually exceed normal baseline. However, this is only demonstrated in Alzheimer's disease models; human data is absent.

How does P21's adamantane modification help it work?

The adamantane moiety attached to P21 enables blood-brain barrier penetration, allowing the peptide to reach brain tissue despite being a ~1,100 Da molecule that normally couldn't cross. This modification is critical to its mechanism and differentiates it from other neuroprotective peptides.